86 related articles for article (PubMed ID: 18155245)
1. Differential recognition of phosphorylated transactivation domains of p53 by different p300 domains.
Polley S; Guha S; Roy NS; Kar S; Sakaguchi K; Chuman Y; Swaminathan V; Kundu T; Roy S
J Mol Biol; 2008 Feb; 376(1):8-12. PubMed ID: 18155245
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation.
Feng H; Jenkins LM; Durell SR; Hayashi R; Mazur SJ; Cherry S; Tropea JE; Miller M; Wlodawer A; Appella E; Bai Y
Structure; 2009 Feb; 17(2):202-10. PubMed ID: 19217391
[TBL] [Abstract][Full Text] [Related]
3. Posttranslational modifications affect the interaction of S100 proteins with tumor suppressor p53.
van Dieck J; Teufel DP; Jaulent AM; Fernandez-Fernandez MR; Rutherford TJ; Wyslouch-Cieszynska A; Fersht AR
J Mol Biol; 2009 Dec; 394(5):922-30. PubMed ID: 19819244
[TBL] [Abstract][Full Text] [Related]
4. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.
Di Agostino S; Strano S; Emiliozzi V; Zerbini V; Mottolese M; Sacchi A; Blandino G; Piaggio G
Cancer Cell; 2006 Sep; 10(3):191-202. PubMed ID: 16959611
[TBL] [Abstract][Full Text] [Related]
5. Complex regulation of the transactivation function of hypoxia-inducible factor-1 alpha by direct interaction with two distinct domains of the CREB-binding protein/p300.
Ruas JL; Berchner-Pfannschmidt U; Malik S; Gradin K; Fandrey J; Roeder RG; Pereira T; Poellinger L
J Biol Chem; 2010 Jan; 285(4):2601-9. PubMed ID: 19880525
[TBL] [Abstract][Full Text] [Related]
6. Acetylation of Sirt2 by p300 attenuates its deacetylase activity.
Han Y; Jin YH; Kim YJ; Kang BY; Choi HJ; Kim DW; Yeo CY; Lee KY
Biochem Biophys Res Commun; 2008 Oct; 375(4):576-80. PubMed ID: 18722353
[TBL] [Abstract][Full Text] [Related]
7. Structural features of human histone acetyltransferase p300 and its complex with p53.
Banerjee S; Arif M; Rakshit T; Roy NS; Kundu TK; Roy S; Mukhopadhyay R
FEBS Lett; 2012 Nov; 586(21):3793-8. PubMed ID: 23010591
[TBL] [Abstract][Full Text] [Related]
8. Skp2 suppresses p53-dependent apoptosis by inhibiting p300.
Kitagawa M; Lee SH; McCormick F
Mol Cell; 2008 Feb; 29(2):217-31. PubMed ID: 18243116
[TBL] [Abstract][Full Text] [Related]
9. Monomeric but not trimeric clathrin heavy chain regulates p53-mediated transcription.
Ohmori K; Endo Y; Yoshida Y; Ohata H; Taya Y; Enari M
Oncogene; 2008 Apr; 27(15):2215-27. PubMed ID: 17952123
[TBL] [Abstract][Full Text] [Related]
10. p53-mediated downregulation of H ferritin promoter transcriptional efficiency via NF-Y.
Faniello MC; Di Sanzo M; Quaresima B; Baudi F; Di Caro V; Cuda G; Morrone G; Del Sal G; Spinelli G; Venuta S; Costanzo F
Int J Biochem Cell Biol; 2008; 40(10):2110-9. PubMed ID: 18372207
[TBL] [Abstract][Full Text] [Related]
11. Exploring the binding affinities of p300 enzyme activators CTPB and CTB using docking method.
Devipriya B; Parameswari AR; Rajalakshmi G; Palvannan T; Kumaradhas P
Indian J Biochem Biophys; 2010 Dec; 47(6):364-9. PubMed ID: 21355420
[TBL] [Abstract][Full Text] [Related]
12. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
[TBL] [Abstract][Full Text] [Related]
13. Autoacetylation induced specific structural changes in histone acetyltransferase domain of p300: probed by surface enhanced Raman spectroscopy.
Arif M; Kumar GV; Narayana C; Kundu TK
J Phys Chem B; 2007 Oct; 111(41):11877-9. PubMed ID: 17894486
[TBL] [Abstract][Full Text] [Related]
14. Tumor Suppressor p53-Mediated Structural Reorganization of the Transcriptional Coactivator p300.
Ghosh R; Kaypee S; Shasmal M; Kundu TK; Roy S; Sengupta J
Biochemistry; 2019 Aug; 58(32):3434-3443. PubMed ID: 31314496
[TBL] [Abstract][Full Text] [Related]
15. Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation.
Jenkins LM; Yamaguchi H; Hayashi R; Cherry S; Tropea JE; Miller M; Wlodawer A; Appella E; Mazur SJ
Biochemistry; 2009 Feb; 48(6):1244-55. PubMed ID: 19166313
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of complex phosphopeptides as mimics of p53 functional domains.
Varadi G; Otvos L
J Pept Sci; 2002 Nov; 8(11):621-33. PubMed ID: 12487430
[TBL] [Abstract][Full Text] [Related]
17. The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors.
Kannan S; Partridge AW; Lane DP; Verma CS
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795143
[TBL] [Abstract][Full Text] [Related]
18. Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity.
Han Y; Jeong HM; Jin YH; Kim YJ; Jeong HG; Yeo CY; Lee KY
Biochem Biophys Res Commun; 2009 May; 383(1):88-92. PubMed ID: 19344692
[TBL] [Abstract][Full Text] [Related]
19. Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein.
Krois AS; Ferreon JC; Martinez-Yamout MA; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):E1853-62. PubMed ID: 26976603
[TBL] [Abstract][Full Text] [Related]
20. Identification of a function-specific mutation of clathrin heavy chain (CHC) required for p53 transactivation.
Ohata H; Ota N; Shirouzu M; Yokoyama S; Yokota J; Taya Y; Enari M
J Mol Biol; 2009 Dec; 394(3):460-71. PubMed ID: 19766654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
